Cannabinoid receptor antagonists and obesity

Current Opinion in Investigational Drugs

Volumn 5, Issue 4, 2004, Pages 389-394

  Black, Shawn C ^a  

^a PFIZER INC   (United States)

Author keywords

Anorectic; Cannabinoid receptor; Endocannabinoid; Obesity; Rimonabant; SR 141716

Indexed keywords

ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; ENDOCANNABINOID;

APPETITE; DRUG ANTAGONISM; HUMAN; METABOLISM; OBESITY; PHYSIOLOGY; REVIEW;

ANTI-OBESITY AGENTS; APPETITE; ENDOCANNABINOIDS; HUMANS; OBESITY; RECEPTOR, CANNABINOID, CB1; RECEPTORS, CANNABINOID;

EID: 3042571675     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258(5090):1946-1949.
2. Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, Di Marzo V: Noladin ether, a putative novel endocannabinoid: Inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett (2002) 513(2-3):294-298.
3. 1 receptor. Proc Natl Acad Sci USA (2001) 98(7):3662-3665.
4. 1 receptor. J Pharmacol Exp Ther (2002) 301(3):1020-1024.
5. 1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J Biol Chem (1999) 274(7):2794-2801.
6. Oka S, Tsuchie A, Tokumura A, Muramatsu M, Suhara Y, Takayama H, Waku K, Sugiura T: Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J Neurochem (2003) 85(6):1374-1381.
7. Deutsch DG, Chin SA: Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol (1993) 46(5):791-796.
8. 1 cannabinoid receptor expression in the mouse brain: Evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience (2003) 119(2):481-496.
9. 1 receptor in rat brain. Proc R Soc Lond B Biol Sci (1998) 265(1410):2081-2085.
10. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D: Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (1994) 372(6507):686-691.
11. Giuffrida A, Beltramo M, Piomelli D: Mechanisms of endocannabinoid inactivation: Biochemistry and pharmacology. J Pharmacol Exp Ther (2001) 298(1):7-14.
12. Gaoni Y, Mechoulam R: Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc (1964) 86(8):1646-1647.
13. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R et al: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 54(2):161-202.
14. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 346(6284):561-564.
15. Gerard CM, Mollereau C, Vassart G, Parmentier M: Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J (1991) 279(1):129-134.
16. Klein TW, Newton C, Friedman H: Cannabinoid receptors and immunity. Immunol Today (1998) 19(8):373-381.
17. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365(6441):61-65.
18. Wiley JL, Martin BR: Cannabinoid pharmacology: Implications for additional cannabinoid receptor subtypes. Chem Phys Lipids (2002) 121(1-2):57-63.
19. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P: Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem (1995) 232(1):54-61.
20. Klein TW, Newton CA, Friedman H: Cannabinoids and the immune system. Pain Res Manag (2001) 6(2):95-101.
21. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F et al: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest (2003) 112(3):423-431.
22. Izzo AA, Mascolo N, Capasso F: The gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol (2001) 1(6):597-603.
23. Partosoedarso ER, Abrahams TP, Moerschbaecher JM, Hornby PJ: Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol (2003) 550(1):149-158.
24. 1 cannabinoid receptor-dependent modulation of feeding. J Neurosci (2002) 22(21):9612-9617.
25. 1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta. Placenta (2003) 24(5):473-478.
26. 1 in the human prostate gland. Prostate (2003) 54(2):95-102.
27. 1 cannabinoid receptor mRNA and protein. Eur J Neurosci (2000) 12(3):1123-1127.
28. Onaivi ES, Leonard CM, Ishiguro H, Zhang PW, Lin Z, Akinshola BE, Uhl GR: Endocannabinoids and cannabinoid receptor genetics. Prog Neurobiol (2002) 66(5):307-344.
29. 2 receptors. Pharmacol Ther (1997) 74(2):129-180.
30. 1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci (1999) 19(11):4544-4558.
31. Freund TF, Katona I, Piomelli D: Role of endogenous cannabinoids in synaptic signaling. Physiol Rev (2003) 83(3):1017-1066.
32. Ohno-Shosaku T, Maejima T, Kano M: Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron (2001) 29(3):729-738.
33. Kreitzer AC, Regehr WG: Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron (2001) 29(3):717-727.
34. Abel EL: Cannabis: Effects on hunger and thirst. Behav Biol (1975) 15(3):255-281.
35. 9-THC. Physiol Behav (1998) 65(2):343-346.
36. Foltin RW, Fischman MW, Byrne MF: Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite (1988) 11(1):1-14.
37. 1) receptors. Psychopharmacology (1999) 143(3):315-317.
38. Jamshidi N, Taylor DA: Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol (2001) 134(6):1151-1154.
39. Kirkham TC, Williams CM, Fezza F, Di Marzo V: Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol (2002) 136(4):550-557.
40. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 410(6830):822-825.
41. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett (1994) 350(2-3):240-244.
42. 1) receptors. Psychopharmacology (1997) 132(1):104-106.
43. 1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol (1998) 9(2):179-181.
44. 1 receptors and obesity. Symposium on the Cannabinoids, El Escorial, Spain (2001):101.
45. Le Fur G: Cannabinoids and feeding behavior. First European Workshop on Cannabinoid Research, Madrid, Spain (2003):29.
46. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL: Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci (1998) 63(8):PL113-PL117.
47. 1 receptor antagonist treatment in dietinduced obese mice. Eur J Pharmacol (2003) 462(1-3):125-132.
48. 1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol (2003) 284(2):R345-R353.
49. 1) receptors in specific extrahypothalamic regions of rats with dietary obesity: A role for endogenous cannabinoids in driving appetite for palatable food? Brain Res (2002) 952(2):232-238.
50. Kirkham TC, Williams CM: Synergistic efects of opioid and cannabinoid antagonists on food intake. Psychopharmacology (2001) 153(2):267-270.
51. 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav (2002) 71(1-2):333-340.
52. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG: Central nervous system control of food intake. Nature (2000) 404(6778):661-671.
53. 1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci (1999) 11(12):4213-4225.
54. 1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry (2001) 58(4):322-328.
55. Pertwee RG: Cannabinoids and the gastrointestinal tract. Gut (2001) 48(6):859-867.
56. 1 receptors in human ileum. Br J Pharmacol (1998) 125(7):1393-1395.
57. 1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol (2001) 134(3):563-570.
58. Mancinelli R, Fabrizi A, Del Monaco S, Azzena GB, Vargiu R, Colombo GC, Gessa GL: Inhibition of peristaltic activity by cannabinoids in the isolated distal colon of mouse. Life Sci (2001) 69(1):101-111.